🧬 ICD-10 CM Z79.85 — Long-Term (Current) Use of Injectable Non-Insulin Antidiabetic Drugs
Billable Code Confirmed
ICD-10 CM Z79.85 is a fully specified, five-character billable code reportable on inpatient and outpatient claims throughout FY2026 (October 1, 2025-September 30, 2026).¹ The fifth character “5” completes the Z79.8 subcategory, distinguishing this drug class from siblings covering aspirin, bisphosphonates, oral hypoglycemics, and estrogen-affecting agents. No further extension is required, and the code is exempt from POA reporting, simplifying its use as a routine secondary diagnosis.¹ Because it’s drug-based rather than diagnosis-based, it’s correctly assignable any time documentation confirms ongoing therapy with the relevant drug class, independent of which underlying condition prompted the prescription.⁴
Non-Billable Parent Codes
Z79 — Long term (current) drug therapy: this three-character category is never billable alone; it requires a fourth character identifying the specific drug class (anticoagulants, insulin, steroids, etc.) before a claim can process. Z79.8 — Other long term (current) drug therapy: this four-character subcategory is also non-billable since it groups several distinct injectable, oral, and hormonal agents together; a fifth character (.81-.85, or further to .89x) is required to specify which “other” class applies.
Clinical Context
The choice between Z79.85 and its closest siblings depends entirely on which drug class is documented, not on diabetes severity, since GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide are pharmacologically and clinically distinct from oral hypoglycemics (Z79.84) and from insulin itself (Z79.4). This has taken on new significance perioperatively: unlike oral agents or insulin, this drug class carries documented concerns about delayed gastric emptying and aspiration risk under anesthesia, making accurate capture clinically meaningful for surgical risk stratification across urology, ophthalmology, and OTO admissions.⁵⁶ Selection also matters because the rapid growth of this class for obesity and cardiometabolic indications means coders will increasingly see Z79.85 in non-diabetic patients, a use current consultancy guidance supports despite the code’s diabetes-oriented title.⁴
Code Classification
ICD-10 CM Z79.85 is a diagnosis code — specifically a Chapter 21 “factors influencing health status” status code — not a procedure, modifier, or HCPCS code. It is never reported as a principal diagnosis under Medicare Code Editor logic and functions strictly as a secondary/additional diagnosis describing an ongoing circumstance of care.²
🔍 Code Description
ICD-10 CM Z79.85 captures a patient’s ongoing, long-term use of an injectable antidiabetic medication that isn’t insulin — a drug class built around glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide, liraglutide, dulaglutide, and exenatide, plus the newer dual GIP/GLP-1 agonist tirzepatide. These agents stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, mechanisms that explain both their therapeutic versatility and the perioperative aspiration-risk concerns now embedded in current anesthesia literature.⁵⁶ Although the official title references “antidiabetic” use, the explosive growth of this class for chronic weight management and cardiometabolic risk reduction means the code is now commonly assigned in patients without a diabetes diagnosis at all, a use that aligns with how siblings Z79.82 (long-term aspirin) and Z79.83 (long-term bisphosphonates) are likewise assigned based on the medication rather than the underlying disease.⁴ Long-term use, per ICD-10-CM convention, generally describes therapy extending beyond roughly three months rather than a single short course, distinguishing Z79.85 from temporary acute-care administration that wouldn’t warrant a status code at all.
Within the Z79 category, Z79.85 sits alongside Z79.84 (oral hypoglycemics) and Z79.4 (insulin) as one of three parallel pathways for documenting antidiabetic pharmacotherapy, and all three may be reported simultaneously when a regimen genuinely combines drug classes, such as basal insulin paired with a weekly GLP-1RA injection. Inpatient profee coders in surgical specialties will most often encounter Z79.85 as an incidental secondary diagnosis on patients admitted for an unrelated urologic, ophthalmologic, or otolaryngologic procedure, where its presence flags a comorbidity relevant to anesthesia planning, glycemic monitoring, and nutritional status during the stay. Because it’s POA-exempt and carries no CC/MCC weight under current MS-DRG logic, its coding value is informational and clinical rather than reimbursement-driving.⁷ Coders should still capture it consistently, since under-reporting Z79 status codes is a recognized data-quality gap given how large this patient population has become.
🌳 Code Tree / Hierarchy
Z79 Long term (current) drug therapy ❌ Non-billable (category)
│
├── Z79.4 Long term (current) use of insulin ✅ Billable
├── Z79.2 Long term (current) use of antibiotics ✅ Billable
│
├── Z79.8 Other long term (current) drug therapy ❌ Non-billable (subcategory this code belongs to)
│ │
│ ├── Z79.82 Long term (current) use of aspirin ✅ Billable
│ ├── Z79.84 Long term (current) use of oral hypoglycemic drugs ✅ Billable
│ └── Z79.85 Long-term (current) use of injectable non-insulin antidiabetic drugs ◀ THIS CODE ✅ Billable
│
└── Z79.89 Other long term (current) drug therapy ❌ Non-billable (further subdivision required)
└── Z79.899 Other long term (current) drug therapy ✅ Billable
Specificity Over the Catch-All
Tip
Sibling codes Z79.81 through Z79.85 are mutually exclusive only in the sense that each describes a different drug class; a patient can legitimately carry several at once (aspirin plus a GLP-1RA, for example), so review the full medication list rather than stopping at the first applicable Z79.8x match.
✅ Includes
- Current, ongoing use of semaglutide injections (Ozempic, Wegovy), regardless of whether the documented indication is diabetes or weight management.
- Current, ongoing use of liraglutide injections (Victoza, Saxenda).
- Current, ongoing use of dulaglutide injections (Trulicity).
- Current, ongoing use of tirzepatide injections (Mounjaro, Zepbound) — the dual GIP/GLP-1 agonist still falls under this code despite its dual mechanism.
- Current, ongoing use of exenatide injections (Byetta, Bydureon).
- Long-term prophylactic or maintenance therapy with any injectable non-insulin antidiabetic agent not otherwise specifically classified elsewhere in the Z79 category.
❌ Excludes
Excludes 1
No Excludes1 notes are published for Z79.85, its Z79.8 parent, or the Z79 category parent in the FY2026 Tabular List.¹ This is clinically meaningful on its own: it confirms there’s no mutual-exclusivity barrier preventing Z79.85 from being reported alongside the diabetes, obesity, or cardiovascular diagnosis the drug actually treats — the combination coders will use in the overwhelming majority of encounters.
Danger
The most common Excludes1-type error here is assuming, incorrectly, that a Z79.8x drug-therapy status code can’t coexist with the disease it’s treating. The Official Guidelines expect both the disease code (e.g., E11.9) and the corresponding Z79 status code together whenever documentation supports it — omitting Z79.85 out of a mistaken exclusivity assumption is itself the pitfall.²
Excludes 2
F11-F19 — Drug abuse and dependence: carried down from the Z79 category level, this clarifies that substance abuse/dependence diagnoses are entirely separate from Z79.85’s depiction of prescribed, therapeutic long-term use; both may be reported together when a patient has a documented substance use disorder and legitimate GLP-1RA therapy for an unrelated condition.² O99.32- — Drug use complicating pregnancy, childbirth, and the puerperium: when injectable antidiabetic use complicates a pregnancy episode, the obstetric-specific code captures that complication while Z79.85 may still be reported concurrently to specify exactly which drug class is involved.²
📋 Clinical Overview
GLP-1RA vs. Oral Hypoglycemics vs. Insulin: Route, Indication, and Perioperative Risk
The decision to assign Z79.85 instead of Z79.84 or Z79.4 depends entirely on which class of antidiabetic medication is documented, not on diabetes severity. Because all three codes can be reported together on a single combination-therapy patient, the real coding skill is reviewing the full medication list line by line rather than stopping at the first antidiabetic status code found. The table below summarizes the distinctions most relevant to inpatient profee coders in surgical specialties, particularly the perioperative risk profile unique to the GLP-1RA class.
| Feature | Z79.85 | Z79.84 | Z79.4 |
|---|---|---|---|
| Drug class & route | Injectable GLP-1 receptor agonists and dual GIP/GLP-1 agonists, given subcutaneously daily or weekly. | Oral agents (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, TZDs) taken by mouth. | Insulin in any formulation, given by injection or pump. |
| Typical indication | Type 2 diabetes; increasingly off-label for obesity, cardiovascular risk, and CKD protection. | First/second-line oral therapy, often layered before injectables are added. | Type 1 diabetes (always required) or advanced type 2 with beta-cell failure; also gestational diabetes and inpatient glycemic protocols. |
| Perioperative/anesthesia note | Subject to current multisociety guidance on delayed gastric emptying/aspiration risk; most patients now continue therapy per individualized shared decision-making.⁵⁶ | Generally held the morning of surgery to avoid hypoglycemia during NPO status; minimal aspiration-risk literature by comparison. | Requires careful perioperative dose adjustment (often reduced basal dose) to avoid hypoglycemia during fasting; no comparable gastric-emptying/aspiration concern. |
Important
Documentation referencing a brand name alone — Ozempic, Trulicity, Mounjaro, Victoza, Byetta — without the generic class or duration should trigger a CDI query confirming both the specific agent (to support Z79.85 versus a different Z79.8x code) and that use genuinely extends beyond the roughly three-month “long-term” threshold.
Associated Clinical Considerations
- Gastrointestinal effects: nausea, vomiting, and delayed gastric emptying are common dose-dependent side effects and the central focus of perioperative aspiration-risk guidance.⁵⁶
- Hypoglycemia risk: low intrinsic risk from GLP-1RAs alone, but combination therapy with insulin or sulfonylureas meaningfully raises it and warrants closer inpatient glucose monitoring.
- Injection site reactions: localized erythema, induration, or lipodystrophy at subcutaneous sites, generally self-limited.
- Pancreatitis signal: rare but reported association; new epigastric pain in a patient on this class should prompt clinical correlation, not automatic dismissal as a side effect.
- Weight loss/nutritional status: significant weight loss is an expected therapeutic effect that may itself prompt separate nutrition-related diagnoses requiring their own documentation and codes.
Tip
These aren’t “manifestations” in the traditional diagnosis-code sense, since Z79.85 is a status code rather than a disease classification. But documenting them helps distinguish an expected medication effect from an emerging complication that warrants its own diagnosis code and CDI query.
💰 HCC Risk Adjustment
| Risk Adjustment Model | HCC Mapping | Practical Impact |
|---|---|---|
| CMS-HCC (Medicare Advantage, v28) | Not mapped | Zero RAF weight on its own |
| HHS-HCC (ACA Marketplace) | Not mapped | Zero RAF weight on its own |
| State Medicaid managed-care models | Model-dependent; some states weight pharmacy-claims data rather than this ICD-10-CM code directly | May influence capitation indirectly through pharmacy utilization, not through Z79.85 itself |
ICD-10 CM Z79.85 carries no RAF weight under current CMS-HCC logic, unlike genuinely HCC-mapped Z-code categories such as transplant status, dialysis dependence, or device-dependence codes. Its risk-adjustment value is indirect: accurate capture strengthens the clinical narrative supporting the underlying diabetes or obesity diagnosis as active and currently managed. Across Medicare, Wisconsin Medicaid, and commercial payers, treat this as a medical-necessity and population-health data point rather than a direct reimbursement lever.
🏥 MS-DRG Assignment
| MDC | DRG with MCC | DRG with CC | DRG without CC/MCC |
|---|---|---|---|
| N/A | N/A | N/A | N/A |
ICD-10 CM Z79.85 can’t anchor an MDC or generate its own DRG triad — it’s barred from principal diagnosis use, so it rides along as a secondary diagnosis under whatever DRG the actual reason for admission generates.⁷ Historically, Z79 long-term drug therapy codes haven’t carried CC/MCC designation, though that’s worth re-checking against the live grouper each fiscal year rather than assuming permanence. The pitfall: assuming this code moves the needle on reimbursement when its real value is comorbidity completeness.
🔗 Related ICD-10-CM Codes
Other Z79 Long-Term Drug Therapy Codes: Z79.4, Z79.82, Z79.83, Z79.84, Z79.899 — the parallel sibling set covering insulin, aspirin, bisphosphonates, oral hypoglycemics, and other unspecified long-term drug therapy.
Commonly Co-Reported Underlying Diagnoses: E11.9, E11.65, E11.22, E66.01 — type 2 diabetes without complications, with hyperglycemia, with diabetic CKD, and morbid obesity, respectively, reflecting the range of indications now driving GLP-1RA prescribing.
🛠️ Commonly Associated CPT Codes
82947 — Glucose, quantitative, blood: routine inpatient monitoring lab for patients on this drug class, especially when combined with insulin or sulfonylureas. 83036 — Hemoglobin A1c: tracks overall glycemic control to guide therapy adjustment; shouldn’t be reported more than once per testing episode per current CPT guidance. 95250 — Continuous glucose monitoring, sensor placement: relevant when a patient is established on CGM alongside GLP-1RA therapy; captures the technical placement/calibration component. 95251 — Continuous glucose monitoring, analysis and interpretation: the professional-interpretation component split from 95250; both shouldn’t be billed by the same provider for the same monitoring period without clear component delineation. 99232 — Subsequent hospital care, per day (moderate complexity): the representative inpatient E/M level for ongoing GLP-1RA/diabetes management documented during an otherwise unrelated surgical admission.
NCCI Bundling Considerations
CPT 82947 and 83036 are distinct lab code families and aren’t subject to NCCI PTP bundling against each other, though both may fold into a defined panel code if ordered as a panel rather than individually. 95250 and 95251 carry their own technical/professional component-split logic and shouldn’t both be billed by the same provider for the identical monitoring period. None of these lab/monitoring codes bundle into 99232 under current NCCI logic, though documentation should independently support medical necessity for each same-day service.
🔬 ICD-10-PCS Crosswalk
3E013GC — Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach: the most likely PCS administration code if hospital staff, rather than the patient, physically administer a dose of the injectable non-insulin antidiabetic agent during the inpatient stay, since current PCS Administration tables carry no dedicated GLP-1RA-specific substance qualifier.⁸ 3E013VG — Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach: included only as a contrast reference for combination-therapy patients also carrying Z79.4, since facility-administered insulin doses generate this distinct code separate from any GLP-1RA administration.⁸
ICD-10 CM Z79.85 itself has no inherent procedural correlate — the PCS crosswalk only becomes relevant on the rare inpatient stay where the facility, not the patient at home, draws up and administers the injection.
💊 Coding Scenarios and Examples
Scenario 1 (Urology): A 64-year-old male with long-standing type 2 diabetes managed on weekly semaglutide is admitted for elective robotic-assisted radical prostatectomy for biopsy-confirmed adenocarcinoma. Per current multisociety perioperative guidance, the anesthesia and surgical team continue semaglutide through the admission given his low aspiration-risk profile and stable glycemic control, documenting the shared decision in the H&P. Hospitalist medicine monitors glucose alongside opioid analgesia postoperatively, and he’s discharged on POD2 without complication. Coding: Principal diagnosis C61 (malignant neoplasm of prostate); principal procedure per the robotic prostatectomy PCS resection code; secondary diagnoses E11.9 and Z79.85. Sequencing: The malignancy/procedure driving admission is principal; E11.9 and Z79.85 are secondary comorbidity codes. CDI note: If documentation only says “on semaglutide” without indicating duration, query to confirm chronic (>3 month) use rather than new initiation before assigning Z79.85.
Scenario 2 (Ophthalmology): A 71-year-old woman with type 2 diabetes complicated by proliferative diabetic retinopathy, on weekly dulaglutide for two years, is admitted for pars plana vitrectomy for tractional retinal detachment. Anesthesia notes she continued her usual dulaglutide schedule preoperatively per current consensus guidance, having no symptoms of delayed gastric emptying. Postoperative course is uncomplicated. Coding: Principal diagnosis the laterality-specific traction retinal detachment code (H33.4- family); secondary diagnoses the fully-specified diabetic retinopathy combination code from the E11.3- family and Z79.85. Sequencing: The eye condition prompting surgery is principal; diabetes-with-retinopathy and Z79.85 are secondary. CDI note: Confirm laterality and macular edema status for the E11.3- code separately — Z79.85 itself needs no laterality and is assigned independent of which eye is affected.
Scenario 3 (OTO): A 58-year-old man with type 2 diabetes and obesity, on long-term tirzepatide for combined glycemic and weight management, is admitted for total laryngectomy with neck dissection for biopsy-proven glottic squamous cell carcinoma. Given the airway-focused nature of the surgery, the team elects to hold tirzepatide for one week per shared decision-making with the prescribing physician, bridging with a short-acting sulfonylurea; the rationale is clearly documented. Coding: Principal diagnosis C32.0 (malignant neoplasm, glottis); secondary diagnoses E11.9, E66.01, and Z79.85. Sequencing: The malignancy and procedure are principal; diabetes, obesity, and the GLP-1RA status code are secondary. CDI note: A temporary perioperative hold doesn’t erase chronic-use status — Z79.85 should still be assigned. Query only if documentation suggests permanent discontinuation rather than a planned surgical bridge.
⚠️ Coding Pitfalls and Tips
Don’t default to the catch-all. Coders shouldn’t reach for Z79.899 when a specific injectable non-insulin agent is named; Z79.85 is the AMA/NCHS-intended code whenever semaglutide, liraglutide, dulaglutide, tirzepatide, or exenatide is identified by name, and using the catch-all when a more specific code is available is an audit-flaggable specificity miss.
Principal diagnosis edit. Z79.85, like all Z79 codes, sits on CMS’s “unacceptable as principal diagnosis” Medicare Code Editor list; submitting it alone in the principal position will reject the claim, so it must always trail the condition or procedure that actually drove the admission.²
Combination therapy double-coding. When documentation shows both insulin and an injectable non-insulin antidiabetic — a common basal-insulin-plus-GLP-1RA regimen — report both Z79.4 and Z79.85 together; neither supersedes the other since each captures a distinct pharmacologic class.
Non-diabetic indication ambiguity. Because GLP-1RAs are now widely prescribed off-label for obesity and cardiometabolic risk, some coders assume Z79.85 requires a diabetes diagnosis on the chart. Current consultancy guidance holds the code is drug-based, not diagnosis-based, so it remains appropriate in non-diabetic patients pending any future official Coding Clinic ruling.⁴
POA reporting fatigue. Z79.85 is exempt from present-on-admission reporting, so don’t spend audit time chasing a POA indicator for this code specifically — though the underlying diabetes or obesity diagnosis driving the therapy will still typically need its own POA determination.¹
Perioperative hold doesn’t erase the code. If anesthesia/surgical documentation notes the GLP-1RA was held or bridged for a procedure per current ASA/multisociety guidance, still capture Z79.85 to reflect established long-term therapy status — a temporary hold is clinically distinct from discontinuation and shouldn’t be miscoded as if the patient were off the medication.⁵⁶
📚 Sources
1. Centers for Medicare & Medicaid Services / National Center for Health Statistics. ICD-10-CM Tabular List, FY2026 (effective October 1, 2025). 2026.2. Centers for Medicare & Medicaid Services / National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. 2026.
3. AAPC Codify. "ICD-10 Code for Long-term (current) use of injectable non-insulin antidiabetic drugs — Z79.85." 2026.
4. Huey K, Kuehn L. "ERRATA: Coding of GLP-1A for Non-Diabetic Patients." Libman Education. 2025.
5. American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. 2023; guidance updated October 2024.
6. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clinical Gastroenterology and Hepatology. 2024.
7. Centers for Medicare & Medicaid Services. MS-DRG Definitions Manual, Version 43.0, FY2026. 2026.
8. icd10data.com. ICD-10-PCS Section 3E0 (Administration, Physiological Systems and Anatomical Regions, Introduction) Tables. 2026.